NIAID Halts Eli Lilly COVID-19 Antibody Trial
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has halted a clinical trial evaluating Eli Lilly’s investigational monoclonal antibody, LY-CoV555 (bamlanivimab), in combination with remdesivir for the treatment of COVID-19 patients.
The move comes after the trial’s independent data and safety monitoring board found no clinical benefit and decided not to enroll any more patients in the study. The trial was paused earlier this month due to a safety issue.
Eli Lilly’s CEO Dave Ricks said he still believes LY-CoV555 is effective for patients in early stages of the disease. NIAID’s decision to stop the trial is not expected to impact the company’s application to the FDA for Emergency Use Authorization for treatment of mild-to-moderate nonhospitalized COVID-19 patients.